Ascletis to unveil obesity drug data at ObesityWeek 2025

Ascletis Pharma Inc. announced its intention to present study results for its obesity drug candidates, ASC30 (oral tablet and injection formulations) and a combination of ASC31 and ASC47, at ObesityWeek 2025 in Atlanta, Georgia. The presentations will include a full analysis of a 28-day multiple ascending dose study of the oral GLP-1R biased small molecule agonist ASC30, as well as information on ASC30’s once-monthly treatment and once-quarterly maintenance formulations.

Additionally, data for the GLP-1R/GIPR peptide agonist ASC31 combined with the adipose-targeted THRβ selective small molecule agonist ASC47 will be presented, showing a 119.6% greater weight loss than tirzepatide in DIO mice. ASC30 is a new chemical entity with patent protection until 2044, while ASC31 and ASC47 are in-house discovered agonists.

The presentations are scheduled for November 4 and November 24, 2025, from 7:30 p.m. to 8:30 p.m. EST. Ascletis emphasizes its determination to develop highly differentiated options for obesity treatment, leveraging both small molecule and peptide programs.